Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib

References

• Sung H , Ferlay J , Siegel RL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2021. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Torre LA , Siegel RL , Jemal A . Lung cancer statistics. Adv Exp Med Biol . 2016;893:1–19.26667336
   PubMed Web of Science ®Google Scholar
• Nicholson AG , Chansky K , Crowley J , et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol . 2016;11(3):300–311. doi:10.1016/j.jtho.2015.10.008 26723244
   PubMed Web of Science ®Google Scholar
• Politi K , Herbst RS . Lung cancer in the era of precision medicine. Clin Cancer Res . 2015;21(10):2213–2220. doi:10.1158/1078-0432.CCR-14-2748 25979927
   PubMed Web of Science ®Google Scholar
• Hall RD , Le TM , Haggstrom DE , et al. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res . 2015;4(5):515–523. doi:10.3978/j.issn.2218-6751.2015.06.09 26629420
   PubMed Web of Science ®Google Scholar
• Li B , Wang S , Li C , et al. The kinetic changes of systemic inflammatory factors during bevacizumab treatment and its prognostic role in advanced non-small cell lung cancer patients. J Cancer . 2019;10(21):5082–5089. doi:10.7150/jca.30478 31602260
   PubMed Web of Science ®Google Scholar
• Xie C , Wan X , Quan H , et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci . 2018;109(4):1207–1219. doi:10.1111/cas.13536 29446853
   PubMed Web of Science ®Google Scholar
• Han B , Li K , Zhao Y , et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised Phase II trial (ALTER0302). Br J Cancer . 2018;118(5):654–661. doi:10.1038/bjc.2017.478 29438373
   PubMed Web of Science ®Google Scholar
• Han B , Li K , Wang Q , et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol . 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039 30098152
   PubMed Web of Science ®Google Scholar
• Shen G , Zheng F , Ren D , et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol . 2018;11(1):120. doi:10.1186/s13045-018-0664-7 30231931
   PubMed Web of Science ®Google Scholar
• Naqash AR , Stroud CRG , Butt MU , et al. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. Acta Oncol . 2018;57(6):867–872. doi:10.1080/0284186X.2017.1415460 29241410
   PubMed Web of Science ®Google Scholar
• Laird BJ , Kaasa S , McMillan DC , et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res . 2013;19(19):5456–5464. doi:10.1158/1078-0432.CCR-13-1066 23938289
   PubMed Web of Science ®Google Scholar
• Mei Z , Shi L , Wang B , et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev . 2017;58:1–13. doi:10.1016/j.ctrv.2017.05.005 28602879
   PubMed Web of Science ®Google Scholar
• Sun K , Chen S , Xu J , et al. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol . 2014;140(9):1537–1549. doi:10.1007/s00432-014-1714-3 24878931
   PubMed Web of Science ®Google Scholar
• Bagley SJ , Kothari S , Aggarwal C , et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer . 2017;106:1–7. doi:10.1016/j.lungcan.2017.01.013 28285682
   PubMed Web of Science ®Google Scholar
• Botta C , Barbieri V , Ciliberto D , et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther . 2013;14(6):469–475. doi:10.4161/cbt.24425 23760488
   PubMed Web of Science ®Google Scholar
• Wu D , Nie J , Dai L , et al. Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thorac Cancer . 2019;10(7):1590–1596. doi:10.1111/1759-7714.13120 31183998
   PubMed Web of Science ®Google Scholar
• Chen D , Xu J , Zhao Y , et al. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. J Cancer Res Clin Oncol . 2020;146(2):401–406. doi:10.1007/s00432-019-03064-1 31691871
   PubMed Web of Science ®Google Scholar
• Wang J , Zhao Y , Wang Q , et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. Cancer Biol Med . 2018;15(4):443–451. doi:10.20892/j.issn.2095-3941.2018.0158 30766754
   PubMed Web of Science ®Google Scholar
• Lecot P , Sarabi M , Pereira Abrantes M , et al. Neutrophil heterogeneity in cancer: from biology to therapies. Front Immunol . 2019;10:2155. doi:10.3389/fimmu.2019.02155 31616408
   PubMed Web of Science ®Google Scholar
• Teramukai S , Kitano T , Kishida Y , et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer . 2009;45(11):1950–1958. doi:10.1016/j.ejca.2009.01.023 19231158
   PubMed Web of Science ®Google Scholar
• Zer A , Sung MR , Walia P , et al. Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer. Clin Lung Cancer . 2018;19(5):426–34.e1. doi:10.1016/j.cllc.2018.04.008 29803574
   PubMed Web of Science ®Google Scholar
• Keizman D , Ish-Shalom M , Huang P , et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer . 2012;48(2):202–208. doi:10.1016/j.ejca.2011.09.001 22018713
   PubMed Web of Science ®Google Scholar
• Azam F , Mehta S , Harris AL . Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer . 2010;46(8):1323–1332. doi:10.1016/j.ejca.2010.02.020 20236818
   PubMed Web of Science ®Google Scholar
• Ferrara N . Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol . 2010;17(3):219–224. doi:10.1097/MOH.0b013e3283386660 20308892
   PubMed Web of Science ®Google Scholar
• Simmons CP , Koinis F , Fallon MT , et al. Prognosis in advanced lung cancer–A prospective study examining key clinicopathological factors. Lung Cancer . 2015;88(3):304–309. doi:10.1016/j.lungcan.2015.03.020 25870155
   PubMed Web of Science ®Google Scholar
• Canna K , McArdle PA , McMillan DC , et al. The relationship between tumour T–lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer . 2005;92(4):651–654. doi:10.1038/sj.bjc.6602419 15700032
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG , Passam FH , Perisinakis K , et al. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med . 2002;96(8):553–558. doi:10.1053/rmed.2002.1328 12195834
   PubMed Web of Science ®Google Scholar
• Sierko E , Wojtukiewicz MZ . Platelets and angiogenesis in malignancy. Semin Thromb Hemost . 2004;30:95–108.15034801
   PubMed Web of Science ®Google Scholar